Atagabalin

Atagabalin
Clinical data
ATC code	none;
Identifiers
	IUPAC name [(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid;
CAS Number	223445-75-8;
PubChemCID	9794485;
ChemSpider	7970252;
UNII	JT7957Q2FB;
ChEMBL	ChEMBL593430;
CompTox Dashboard(EPA)	DTXSID80944993;
Chemical and physical data
Formula	C10H19NO2
Molar mass	185.267g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]1CC(C[C@@H]1C)(CC(=O)O)CN;
	InChI InChI=1S/C10H19NO2/c1-7-3-10(6-11,4-8(7)2)5-9(12)13/h7-8H,3-6,11H2,1-2H3,(H,12,13)/t7-,8-/m0/s1; Key:IUVMAUQEZFTTFB-YUMQZZPRSA-N;
	(what is this?)(verify)

Atagabalin(PD-0200,390) is a drug developed byPfizerand related togabapentin,which similarly binds to the α₂δcalcium channels(1and2).^[1]It was under development as a treatment forinsomnia,^[2]^[3]^[4]but was discontinued following unsatisfactory trial results.

References[edit]

^Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC (January 2010). "Synthesis and in vivo evaluation of bicyclic gababutins".Bioorganic & Medicinal Chemistry Letters.20(2): 461–4.doi:10.1016/j.bmcl.2009.11.118.PMID 20005103.
^Corrigan B, Feltner DE, Ouellet D, Werth JL, Moton AE, Gibson G (August 2009)."Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit".British Journal of Clinical Pharmacology.68(2): 174–80.doi:10.1111/j.1365-2125.2009.03444.x.PMC2767279.PMID 19694735.
^Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA (May 2011)."Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: Basic characterization and drug pharmacology".Brain Research.1401:1–9.doi:10.1016/j.brainres.2011.05.025.PMC3197737.PMID 21664606.
^Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (June 2011). "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models".Pharmaceutical Research.28(10): 2610–27.doi:10.1007/s11095-011-0490-x.PMID 21681607.S2CID 22241527.

Thissedative-related article is astub.You can help Wikipedia byexpanding it.

[pmid20005103-1] Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC (January 2010). "Synthesis and in vivo evaluation of bicyclic gababutins".Bioorganic & Medicinal Chemistry Letters.20(2): 461–4.doi:10.1016/j.bmcl.2009.11.118.PMID 20005103.

[pmid19694735-2] Corrigan B, Feltner DE, Ouellet D, Werth JL, Moton AE, Gibson G (August 2009)."Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit".British Journal of Clinical Pharmacology.68(2): 174–80.doi:10.1111/j.1365-2125.2009.03444.x.PMC2767279.PMID 19694735.

[pmid21664606-3] Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA (May 2011)."Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: Basic characterization and drug pharmacology".Brain Research.1401:1–9.doi:10.1016/j.brainres.2011.05.025.PMC3197737.PMID 21664606.

[pmid21681607-4] Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (June 2011). "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models".Pharmaceutical Research.28(10): 2610–27.doi:10.1007/s11095-011-0490-x.PMID 21681607.S2CID 22241527.

[1]

[2]

[3]

[4]

See also[edit]

References[edit]